Picture of Pharmesis International logo

BFK Pharmesis International Share Price

0.000.00%
sg flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapValue Trap

Momentum

Relative Strength (%)
1m-4.14%
3m-23.23%
6m-14.48%
1yr-25.17%
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w Highn/a
50d MAn/a
200d MAn/a

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital5.08%
Return on Equity2.06%
Operating Margin5.96%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Pharmesis International EPS forecast chart

Profile Summary

Pharmesis International Ltd. is a Singapore-based investment holding company. The Company is a pharmaceutical company engaged in the manufacturing of pharmaceutical products, including western medicine in the form of tablets and granules, among others, and traditional Chinese medicine (TCM) formulated products for the treatment of illnesses relating to the liver and gall bladder. It operates in three segments: Western drugs, which refers mainly to chemically formulated drugs marketed under the Kinna brand; TCM formulated drugs, which includes TCM marketed under the Longlife brand, and Distribution, which includes agency products and internally manufactured products marketed through the distribution arm. Its main products are ATT, Gulin Gansu and Er Ding granules. Its subsidiary, Chengdu Kinna Pharmaceutical Co., Ltd, is engaged in the development, manufacture, packaging and sale of western medicines and health tonic products.

Directors

Last Annual
December 31st, 2021
Last Interim
December 31st, 2021
Incorporated
September 29th, 2003
Public Since
October 6th, 2004
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
sg flag iconSingapore Exchange Securities Trading Ltd
Shares in Issue
23,000,000
Blurred out image of a map
Address
No.8 Yingbin Road, CHENGDU
Web
http://www.pharmesis.com
Phone
Auditors
Ernst & Young LLP

BFK Share Price Performance

Upcoming Events for BFK

Similar to BFK

Picture of Haw Par logo

Haw Par

sg flag iconSingapore Exchange Securities Trading Ltd

Picture of Hyphens Pharma International logo

Hyphens Pharma International

sg flag iconSingapore Exchange Securities Trading Ltd

Picture of IX Biopharma logo

IX Biopharma

sg flag iconSingapore Exchange Securities Trading Ltd

Picture of Suntar Eco-City logo

Suntar Eco-City

sg flag iconSingapore Exchange Securities Trading Ltd

FAQ

Or unlock with your email

Or unlock with your email